Our integrated platform is applied end to end across our own programs: target identification, functional binder screening, and computational prediction of on-target and off-target liabilities, coupled with wet lab assessment.
With this, we are working on a pipeline of first-in-class or best-in-class TCEs against various solid tumor indications.
Program
SBT 2611
Indication - Solid tumor
Phase - Preclinical
Program
SBT 2612
Indication - Solid tumor
Phase - Preclinical
Program
SBT 2613
Indication - Solid tumor
Phase - Preclinical
Program
UNdisclosed
Indication - Autoimmunity
Phase - Discovery
Program
Modality
Discovery
Precinical
Clinical
SBT-121,
Small Cell Lung Cancer
Small Cell Lung Cancer
Trispecific Ab-TCE
SBT-201,
Ovarian Cancer
Ovarian Cancer
Ab-TCE
SBT-425,
Hepatocellular Carcinoma
Hepatocellular Carcinoma
TCR-TCE
